Annalisa Jenkins
Showing 1–3 of 3 transcripts.
- Milken Institute58 min
From Stigma to Treatment: Tackling the Global Mental Health Crisis
LaTese Briggs, Lynne Goldberg, Annalisa Jenkins, Elie Karam, Colin Lawlor
A global panel of experts, including Dr. Lattice Briggs, Annalisa Jenkins, and Colin Lawler, highlights a rising mental health crisis driven by chronic stress, sleep deprivation, and systemic barriers that threaten to cost the global economy $16 trillion by 2030. The discussion identifies ignorance, stigma, and an overreliance on institutional "sick care" as primary obstacles, while advocating for a shift toward community-based prevention, digital interventions, and emerging pharmaceuticals like psilocybin. Speakers emphasize that resolving this crisis requires treating mental health as a human rights issue and integrating preventative care into existing community infrastructure to sustain the future global workforce.
- Milken Institute56 min
Asia's Next Frontier: Building Capabilities for Translational Research
Tanisha Carino, Christiana Bardon, Carl Firth, Annalisa Jenkins, Baiju Shah, Chris Bardone
Faster Cures and Milken Institute convene Asian policymakers and industry leaders to address the critical "Valley of Death" separating basic science from clinical cures across the region's rapidly expanding R&D landscape. The discussion highlights Singapore's strategic shift toward translational funding and data infrastructure, China's accelerated regulatory reforms, and the Harrington Project's hybrid model designed to bridge skill and capital gaps for high-burden diseases. While genomic initiatives and reimbursement changes promise to modernize access, the session concludes that overcoming cultural barriers in patient advocacy and workforce specialization remains essential for translating scientific knowledge into effective patient treatments.
- Milken Institute57 min
Advancing Health Technology and Innovation
Jonathan Simons, Chris Austin, Annalisa Jenkins, Richard Merkin, Kim Nguyen, David Spetzler
Leading innovators and policymakers are convening to redefine healthcare delivery through a convergence of genomic editing, artificial intelligence, and cross-disciplinary collaboration rather than incremental improvements. Key figures emphasize leveraging technologies like CRISPR and deep learning to bridge the massive translation gap between molecular discovery and patient treatment, with the goal of curing rare genetic disorders and democratizing precision oncology. The discussion outlines a strategic framework for the UAE to leapfrog legacy systems by deploying high-impact solutions such as organ-on-a-chip models and AI-driven diagnostics to transform untreatable conditions into manageable outcomes within the coming decade.